{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:19:57Z","timestamp":1792790397963,"version":"4.5.0"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T00:00:00Z","timestamp":1548288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2016R1A2B4015192"],"award-info":[{"award-number":["NRF-2016R1A2B4015192"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Unlike tamoxifen, the relationship between aromatase inhibitor use in postmenopausal patients with breast cancer and nonalcoholic fatty liver disease (NAFLD) has not been delineated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>A retrospective analysis of 253 patients with early breast cancer without baseline NAFLD and treated with nonsteroidal aromatase inhibitors was performed. Among them, 220 patients were matched for sex, age, and menstruation status with healthy patients, and the prevalence of NAFLD was compared. NAFLD was determined by hepatic steatosis index in the absence of other known liver diseases. The presence of significant liver fibrosis in patients with NAFLD was determined noninvasively by AST-platelet ratio index, FIB-4 score, and NAFLD fibrosis score (NFS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Postmenopausal patients with breast cancer undergoing treatment with aromatase inhibitors had higher prevalence of NAFLD independent of body mass index (BMI) and underlying diabetes mellitus (DM). Although the aromatase inhibitor group showed higher fibrotic burden by NFS, independent of BMI and DM, the proportion of advanced fibrosis did not show statistically significant differences between AI-treated patients and the healthy patients. Those with abnormal baseline fasting glucose levels are suggested to have increased risk of NAFLD development after aromatase inhibitor treatment. In addition, patients with NAFLD developed after aromatase inhibitor use had significantly lower disease-free survival than those without NAFLD, although there was no significant difference in overall survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Results of this study suggest that inhibition of estrogen synthesis in postmenopausal women undergoing treatment with aromatase inhibitors could increase the risk of NAFLD, which might have some influence on the prognosis of patients with breast cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1634\/theoncologist.2018-0370","type":"journal-article","created":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T16:09:19Z","timestamp":1548346159000},"page":"e653-e661","source":"Crossref","is-referenced-by-count":28,"title":["Aromatase Inhibitors and Newly Developed Nonalcoholic Fatty Liver Disease in Postmenopausal Patients with Early Breast Cancer: A Propensity Score-Matched Cohort Study"],"prefix":"10.1093","volume":"24","author":[{"given":"Jung Il","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Hwan","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Inha University College of Medicine, Incheon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Gwe","family":"Anh","sequence":"additional","affiliation":[{"name":"Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Woong","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon","family":"Jeong","sequence":"additional","affiliation":[{"name":"Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwan Sik","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,1,24]]},"reference":[{"key":"2021122507443171500_R1","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa032312","article-title":"A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer","volume":"349","author":"Goss","year":"2003","journal-title":"N Engl J Med"},{"key":"2021122507443171500_R2","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1200\/JCO.2013.54.2258","article-title":"Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American society of clinical oncology clinical practice guideline focused update","volume":"32","author":"Burstein","year":"2014","journal-title":"J Clin Oncol"},{"key":"2021122507443171500_R3","first-page":"2089","article-title":"In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients","volume":"4","author":"Geisler","year":"1998","journal-title":"Clin Cancer Res"},{"key":"2021122507443171500_R4","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1158\/1078-0432.CCR-04-2187","article-title":"Aromatase inhibition: Translation into a successful therapeutic approach","volume":"11","author":"Geisler","year":"2005","journal-title":"Clin Cancer Res"},{"key":"2021122507443171500_R5","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1634\/theoncologist.11-6-553","article-title":"Aromatase inhibitors in breast cancer: An overview","volume":"11","author":"Altundag","year":"2006","journal-title":"The Oncologist"},{"key":"2021122507443171500_R6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jsbmb.2011.02.001","article-title":"Aromatase, aromatase inhibitors, and breast cancer","volume":"125","author":"Chumsri","year":"2011","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2021122507443171500_R7","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1001\/jama.2015.5370","article-title":"Nonalcoholic fatty liver disease: A systematic review","volume":"313","author":"Rinella","year":"2015","journal-title":"JAMA"},{"key":"2021122507443171500_R8","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-2036.2011.04724.x","article-title":"Systematic review: The epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults","volume":"34","author":"Vernon","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"2021122507443171500_R9","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1007\/s00535-003-1178-8","article-title":"Increase in the prevalence of fatty liver in Japan over the past 12 years: Analysis of clinical background","volume":"38","author":"Kojima","year":"2003","journal-title":"J Gastroenterol"},{"key":"2021122507443171500_R10","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1111\/j.1572-0241.2003.07486.x","article-title":"The prevalence and etiology of elevated aminotransferase levels in the United States","volume":"98","author":"Clark","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"2021122507443171500_R11","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1210\/jc.2003-030242","article-title":"The emergence of the metabolic syndrome with menopause","volume":"88","author":"Carr","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122507443171500_R12","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/ijo.2008.25","article-title":"Increased visceral fat and decreased energy expenditure during the menopausal transition","volume":"32","author":"Lovejoy","year":"2008","journal-title":"Int J Obes (Lond)"},{"key":"2021122507443171500_R13","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1365-2265.2006.02543.x","article-title":"Effects of HRT on liver enzyme levels in women with type 2 diabetes: A randomized placebo-controlled trial","volume":"65","author":"McKenzie","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2021122507443171500_R14","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1002\/hep.26761","article-title":"Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis","volume":"59","author":"Yang","year":"2014","journal-title":"Hepatology"},{"key":"2021122507443171500_R15","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/hep.28514","article-title":"A longer duration of estrogen deficiency increases fibrosis risk among postmenopausal women with nonalcoholic fatty liver disease","volume":"64","author":"Klair","year":"2016","journal-title":"Hepatology"},{"key":"2021122507443171500_R16","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.cgh.2016.07.034","article-title":"Nonalcoholic Steatohepatitis Clinical Research Network. Patient sex, reproductive status, and synthetic hormone use associate with histologic severity of nonalcoholic steatohepatitis","volume":"15","author":"Yang","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2021122507443171500_R17","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.clbc.2016.12.004","article-title":"The relationship between tamoxifen-associated nonalcoholic fatty liver disease and the prognosis of patients with early-stage breast cancer","volume":"17","author":"Yan","year":"2017","journal-title":"Clin Breast Cancer"},{"key":"2021122507443171500_R18","doi-asserted-by":"crossref","first-page":"561","DOI":"10.4093\/dmj.2011.35.6.561","article-title":"Obesity and metabolic syndrome in Korea","volume":"35","author":"Oh","year":"2011","journal-title":"Diabetes Metab J"},{"key":"2021122507443171500_R19","doi-asserted-by":"crossref","first-page":"d7302","DOI":"10.1136\/bmj.d7302","article-title":"Prognosis and staging of non-alcoholic fatty liver disease","volume":"343","author":"Jepsen","year":"2011","journal-title":"BMJ"},{"key":"2021122507443171500_R20","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"2021122507443171500_R21","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/hep.29721","article-title":"Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis","volume":"68","author":"Younossi","year":"2018","journal-title":"Hepatology"},{"key":"2021122507443171500_R22","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.dld.2009.08.002","article-title":"Hepatic steatosis index: A simple screening tool reflecting nonalcoholic fatty liver disease","volume":"42","author":"Lee","year":"2010","journal-title":"Dig Liver Dis"},{"key":"2021122507443171500_R23","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1136\/gut.2010.216077","article-title":"Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease","volume":"59","author":"McPherson","year":"2010","journal-title":"Gut"},{"key":"2021122507443171500_R24","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.cgh.2009.05.033","article-title":"Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease","volume":"7","author":"Shah","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2021122507443171500_R25","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1053\/j.gastro.2013.06.057","article-title":"Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"145","author":"Angulo","year":"2013","journal-title":"Gastroenterology"},{"key":"2021122507443171500_R26","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1002\/hep.20717","article-title":"Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C","volume":"41","author":"Lackner","year":"2005","journal-title":"Hepatology"},{"key":"2021122507443171500_R27","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1055\/s-0028-1091978","article-title":"The epidemiology of nonalcoholic fatty liver disease: A global perspective","volume":"28","author":"Lazo","year":"2008","journal-title":"Semin Liver Dis"},{"key":"2021122507443171500_R28","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/hep.23527","article-title":"The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis","volume":"51","author":"Ascha","year":"2010","journal-title":"Hepatology"},{"key":"2021122507443171500_R29","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1440-1746.2005.04086.x","article-title":"Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults","volume":"21","author":"Park","year":"2006","journal-title":"J Gastroenterol Hepatol"},{"key":"2021122507443171500_R30","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1136\/gut.2006.115345","article-title":"Menopausal status and hepatic steatosis in a general female population","volume":"56","author":"V\u00f6lzke","year":"2007","journal-title":"Gut"},{"key":"2021122507443171500_R31","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejogrb.2015.04.017","article-title":"Menopausal stages and non-alcoholic fatty liver disease in middle-aged women","volume":"190","author":"Ryu","year":"2015","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2021122507443171500_R32","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1136\/gutjnl-2011-300342","article-title":"Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: A population study using proton-magnetic resonance spectroscopy and transient elastography","volume":"61","author":"Wong","year":"2012","journal-title":"Gut"},{"key":"2021122507443171500_R33","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s00535-012-0533-z","article-title":"Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: A multicenter large retrospective study","volume":"47","author":"Eguchi","year":"2012","journal-title":"J Gastroenterol"},{"key":"2021122507443171500_R34","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/hep.24491","article-title":"The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: An international collaborative study","volume":"54","author":"Bhala","year":"2011","journal-title":"Hepatology"},{"issue":"1","key":"2021122507443171500_R35","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jhep.2017.09.012","article-title":"Association between non-alcoholic fatty liver disease and cancer incidence rate","author":"Kim","year":"2018","journal-title":"J Hepatol"},{"key":"2021122507443171500_R36","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/hep.24452","article-title":"Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: A meta-analysis","volume":"54","author":"Hernaez","year":"2011","journal-title":"Hepatology"},{"key":"2021122507443171500_R37","doi-asserted-by":"crossref","first-page":"R183","DOI":"10.1530\/ERC-13-0099","article-title":"Aromatase inhibition 2013: Clinical state of the art and questions that remain to be solved","volume":"20","author":"L\u00f8nning","year":"2013","journal-title":"Endocr Relat Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2018-0370","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2018-0370","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/8\/e653\/41922727\/oncolo_24_8_e653.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/8\/e653\/41922727\/oncolo_24_8_e653.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T02:45:44Z","timestamp":1640400344000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/24\/8\/e653\/6439361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,24]]},"references-count":37,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,1,24]]},"published-print":{"date-parts":[[2019,8,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2018-0370","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,8,1]]},"published":{"date-parts":[[2019,1,24]]}}}